ReviewClinical & experimental metastasis2003
Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer.
Review in Clinical & experimental metastasis, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 136 citations in OpenAlex.
- Erythropoietin-induced hepatocyte receptor A2 regulates effect of pyroptosis on gastrointestinal colorectal cancer occurrence and metastasis resistance.World journal of gastrointestinal oncology · 2024Review
- ProNGF promotes brain metastasis through TrkA/EphA2 induced Src activation in triple negative breast cancer cells.Experimental hematology & oncology · 2023Article
- Combination of protein and cell internalization SELEX identifies a potential RNA therapeutic and delivery platform to treat EphA2-expressing tumors.Molecular therapy. Nucleic acids · 2023Article
- Interactions between EGFR and EphA2 promote tumorigenesis through the action of Ephexin1.Cell death & disease · 2022Article
- Loss of EphA7 Expression in Basal Cell Carcinoma by Hypermethylation of CpG Islands in the Promoter Region.Analytical cellular pathology (Amsterdam) · 2022Article
- Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies.Indian journal of surgical oncology · 2021Article
- Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids.Journal of nanobiotechnology · 2021Article
- EphA2 and EGFR: Friends in Life, Partners in Crime. Can EphA2 Be a Predictive Biomarker of Response to Anti-EGFR Agents?Cancers · 2021Review
- Serum Exosomal EphA2 is a Prognostic Biomarker in Patients with Pancreatic Cancer.Cancer management and research · 2021Article
- EphA2 as a new target for breast cancer and its potential clinical application.International journal of clinical and experimental pathology · 2021Article
- Targeting EphA2 in cancer.Journal of hematology & oncology · 2020Review
- Membrane receptor activation mechanisms and transmembrane peptide tools to elucidate them.The Journal of biological chemistry · 2020Review
- Making Connections: Guidance Cues and Receptors at Nonneural Cell-Cell Junctions.Cold Spring Harbor perspectives in biology · 2018Review
- Dysregulated erythropoietin-producing hepatocellular receptor A2 (EphA2) is involved in tubal pregnancy via regulating cell adhesion of the Fallopian tube epithelial cells.Reproductive biology and endocrinology : RB&E · 2018Article
- Molecular and functional crosstalk between extracellular Hsp90 and ephrin A1 signaling.Oncotarget · 2017Article
- PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Article
- Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and Treatment Monitoring.Nature biomedical engineering · 2017Article
- Article
- Expression of microRNA‑26b and identification of its target gene EphA2 in pituitary tissues in Yanbian cattle.Molecular medicine reports · 2015Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a disease of aberrant signal transduction. The expression and function of intracellular signaling pathways are frequently subverted as cells progress towards a metastatic phenotype. In particular, tyrosine kinases initiate powerful signals that govern many different aspects of cell behavior. In Recent studies have demonstrated that the EphA2 receptor tyrosine kinase is frequently overexpressed and functionally altered in aggressive tumor cells, and that these changes promote metastatic character. Herein, we provide an overview of our current understanding of EphA2, with emphasis upon the differential regulation of EphA2 expression and function. We also show that differential EphA2 expression and function may provide a unique opportunity for selective therapeutic targeting of EphA2 in metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.